BioSpace News Archive

Cingulate Inc. announced the closing of its previously announced public offering of an aggregate of 6,925,208 shares of its common stock, Series A warrants to purchase up to 6,925,208 shares of common stock and Series B warrants to purchase up to 3,462,604 shares of common stock, at a public offering price of $0.5776 per share and accompanying warrants.

Jazz Pharmaceuticals plc announced that Company management will participate in three upcoming investor conferences.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.

Champions Oncology, Inc. announced its financial results for its first quarter of fiscal 2024, ended July 31, 2023.

Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials in Japan.

InnoCare Pharm announced the approval of the Investigational New Drug to conduct the clinical trial of ICP-189, a novel SHP2 allosteric inhibitor, in combination with furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR inhibitor, in China.